Shire To Acquire Rare-Disease Company ViroPharma - - BioPharm International

ADVERTISEMENT

Shire To Acquire Rare-Disease Company ViroPharma


Shire has entered into a merger agreement to acquire all the outstanding shares of the rare disease company ViroPharma for approximately $4.2 billion, Shire announced in a press release. The acquisition fits with Shire’s strategy to expand its rare-disease portfolio and adds a growing commercial product.

ViroPharma’s commercial product Cinryze (C1 esterase inhibitor [human]) is for the prophylactic treatment of hereditary angioedema (HAE). The product complements Shire’s Firazyr (icatibant injection). Cinryze was approved with orphan drug designation in October 2008 and has grown rapidly since its launch in 2009.

“Shire is uniquely positioned to drive the continued success of Cinryze for the benefit of patients through our knowledge of the rare disease space, our international infrastructure, and our biologics manufacturing expertise,” said Shire CEO, Flemming Ornskov, MD, in the press release.

Source: Shire

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here